第一波AI制药公司已经开始合并了。 8月8日，两家AI制药龙头公司Recursion和Exscientia宣布已达成最终协议合并。Recursion是英伟达力挺的AI制药公司，致力于构建大型生物分子生成式AI模型，以实现药物发现的工业化；Exscientia则是更“传统意义”上的AI制药公司，利用高精度数据进行药物筛选、设计与开发。 据报道，Recursion将以6.88亿美元的价格全股票交易收购 ...

Recursion Pharmaceuticals Inc.公布了2026年第一季度财报，整体表现喜忧参半。公司每股亏损（EPS）为-0.22美元，优于分析师预期的-0.26美元，超出预期15.38%。然而，营收表现令人失望，实际营收仅为647万美元，远低于预期的1,628万美元，差距高达60.26%。受营收大幅未达标影响，公司股价在盘前交易中下跌5.34%，报$3.19。

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...

Three companies in particular sit right at the center of that transition: Tempus AI ( TEM 7.53%), Recursion Pharmaceuticals ( ...

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson ...